ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Biomedical Supercomputer Will Be Available To NIH, Extramural Scientists; No Payback Planned To Starts

July 13, 1984

Hammer Signs $2.5 Mil. Check To NCI Fro Stop Cancer Campaign

February 2, 1990

ODAC Votes Against Adria’s Chemoprotector, Okays Leustatin

July 3, 1992

In Brief: CFO Dwain Morris to Leave MD Anderson Cancer Center

May 2, 2014

Terry To Leave As DRCCA Acting Director Sept. 1, Peter Greenwald Is DeVita’s Choice For The Job

August 14, 1981

DCE Board Oks Concept For Three Contracts In Radiation Epidemiology

June 29, 1984